PURPOSE: To report a young patient with choroidal neovascularization (CNV) secondary to Best vitelliform macular dystrophy (BVMD) who recovered good visual acuity with intravitreal bevacizumab (IVB). METHODS: A 6-year-old boy was noted to have diminution of vision in both eyes. His best-corrected visual acuity (BCVA) was 20/40 in the right eye (OD) and 20/160 in the left eye (OS). Detailed examination including slit-lamp biomicroscopy, fluorescein angiography, and optical coherence tomography (OCT) showed active CNV in OS. Two consecutive IVB injections (1.25 mg/0.05 mL) were given in OS. RESULTS: During the follow-up, OD showed minimal subretinal fluid on OCT and was treated with one injection of IVB (1.25 mg/0.05 mL). At 9 months of follow-up, OS BCVA was 20/50 and OD BCVA 20/30 with presence of scarred CNV on fundus examination and OCT in both the eyes. No drug-related ocular or systemic side effects were encountered. CONCLUSIONS: Intravitreal bevacizumab appears to be a promising and cost-effective modality of treatment in CNV associated with BVMD with good visual recovery.
PURPOSE: To report a young patient with choroidal neovascularization (CNV) secondary to Best vitelliform macular dystrophy (BVMD) who recovered good visual acuity with intravitreal bevacizumab (IVB). METHODS: A 6-year-old boy was noted to have diminution of vision in both eyes. His best-corrected visual acuity (BCVA) was 20/40 in the right eye (OD) and 20/160 in the left eye (OS). Detailed examination including slit-lamp biomicroscopy, fluorescein angiography, and optical coherence tomography (OCT) showed active CNV in OS. Two consecutive IVB injections (1.25 mg/0.05 mL) were given in OS. RESULTS: During the follow-up, OD showed minimal subretinal fluid on OCT and was treated with one injection of IVB (1.25 mg/0.05 mL). At 9 months of follow-up, OS BCVA was 20/50 and OD BCVA 20/30 with presence of scarred CNV on fundus examination and OCT in both the eyes. No drug-related ocular or systemic side effects were encountered. CONCLUSIONS: Intravitreal bevacizumab appears to be a promising and cost-effective modality of treatment in CNV associated with BVMD with good visual recovery.